Claims
- 1. A sustained release microcapsule, comprising:
- (a) a pharmaceutically effective compound comprising an amorphous water-soluble 2-piperazinone-1-acetic acid compound of formula (I) or a salt thereof: ##STR55## wherein A.sup.1 and A.sup.2 independently are a group having a nitrogen atom capable of being positively charged or optionally substituted amidoxime, optionally substituted oxadiazolyl or optionally substituted thiadiazolyl;
- D is a 2- to 6-atom chain optionally bonded through a hereto-atom or a 5- or 6-membered carbocyclic ring or heterocyclic ring having 1 to 4 N, O or S hetero-atoms provided that depending on the bonding position of said 5- or 6-membered ring, said ring is counted as a 2- or 3-atom chain in said 2- to 6-atom chain;
- R.sup.1 is a hydrogen atom or a hydrocarbon group;
- R.sup.2 is (1) hydrogen atom or (2) a C.sub.1-4 alkyl group which may be substituted with an optionally substituted phenyl group optionally substituted with C.sub.1-4 alkoxy, hydroxyl group or carbamoyl group, or R.sup.1 and R.sup.2 may be joined together to form a 5- or 6-membered ring;
- P is a 1- to 10-carbon atom chain optionally bonded through a hereto-atom or 5- or 6-membered carbocyclic ring or heterocyclic ring having 1 to 4 N, O or S hetero-atoms provided that depending on the bonding position of said 5- or 6-membered ring, said ring is counted as a 2- or 3-atom chain in said 1- to 10-carbon atom chain;
- Y is (1) a carboxyl group which is optionally esterified with optionally substituted alkoxy, alkenyloxy or benzyloxy, or --OCH(R.sup.7a)OCOR.sup.8 wherein R.sup.7a is hydrogen, straight-chain or branched lower alkyl, or C.sub.5-7 cycloalkyl and R.sup.8 is straight-chain or branched lower alkyl, lower alkenyl, C.sub.5-7 cycloalkyl, lower alkyl substituted with C.sub.5-7 cycloalkyl or optionally substituted C.sub.6-12 aryl, lower alkenyl substituted with C.sub.5-7 cycloalkyl or optionally substituted C.sub.6-12 aryl, optionally substituted aryl, straight-chain or branched lower alkoxy, straight chain or branched lower alkenyloxy, C.sub.5-7 cycloalkyloxy, lower alkoxy substituted with C.sub.5-7 cycloalkyl or optionally substituted C.sub.6-12 aryl, lower alkenyloxy substituted with C.sub.5-7 cycloalkyl or optionally substituted C.sub.6-12 aryl, or optionally substituted C.sub.6-12 aryloxy, or (2) an optionally amidated carboxyl group; and
- n denotes an integer of 0 to 8; and
- (b) a pharmacologically acceptable polymer binder.
- 2. A microcapsule of claim 1, wherein the 2-piperazinone-1-acetic acid compound or salt thereof is dispersed in the polymer.
- 3. A microcapsule of claim 1, wherein the water-solubility of the 2-piperazinone-1-acetic acid compound or salt thereof is not less than about 1 g/100 ml at 20 C.degree..
- 4. A microcapsule of claim 1, wherein the average particle size of the 2-piperazinone-1-acetic acid compound or salt thereof is not more than about 30 .mu.m.
- 5. A microcapsule of claim 1, wherein the average particle size of the 2-piperazinone-1-acetic acid compound or salt thereof is not more than about 5 .mu.m.
- 6. A microcapsule of claim 1, wherein the 2-piperazinone-1-acetic acid compound is (S)-4-(4-guanidinobenzoylamino)acetyl-3-�3-(4-guanidinobenzoylamino)!propyl-2-oxopiperazine-1-acetic acid.
- 7. A microcapsule of claim 1, which comprises (S)-4-(4-guanidinobenzoylamino)acetyl-3-�3-(4-guanidinobenz-oylamino)!propyl-2-oxopiperazine-1-acetic acid hydrochloride.
- 8. A microcapsule of claim 1, wherein the 2-piperazinone-1-acetic acid compound is (S)-4-(4-amidinobenzoyl)aminoacetyl-3-{3-(4-amidinobenzoyl)amino}propyl-2-oxopiperazine-1-acetic acid.
- 9. A microcapsule of claim 1, which comprises (S)-4-(4-amidinobenzoyl)aminoacetyl-3-{3-(4-amidinobenzoyl)amino}propyl-2-oxopiperazine-1-acetic acid trifluoroacetate.
- 10. A microcapsule of claim 1, wherein the 2-piperazinone-1-acetic acid compound is (S)-4-�4-(2-aminoethyl)benzoylamino)acetyl-3-�3-(4-amidinobenzoylamino)!propyl-2-oxopiperazine-1-acetic acid.
- 11. A microcapsule of claim 1, wherein the 2-piperazinone-1-acetic acid compound is (S)-4-(4-amidinobenzoylamino)acetyl-3-�2-(4-guanidinobenzoylamino)!ethyl-2-oxopiperazine-1-acetic acid.
- 12. A microcapsule of claim 1, wherein the 2-piperazinone-1-acetic acid compound is (S)-4-(4-amidinobenzoyl)aminoacetyl-3-�3-(4-guanidinobutan-oylamino)!propyl-2-oxopiperazine-1-acetic acid.
- 13. A microcapsule of claim 1, wherein the polymer is a biodegradable polymer.
- 14. A microcapsule of claim 13, wherein the biodegradable polymer is a polyester.
- 15. A microcapsule of claim 14, wherein the polyester is a lactic acid/glycolic acid copolymer or homopolymer.
- 16. A microcapsule of claim 15, wherein the molar ratio of lactic acid/glycolic acid of the copolymer or homopolymer is from about 100/0 to about 25/75.
- 17. A microcapsule of claim 15, wherein the weight average molecular weight of the lactic acid/glycolic acid copolymer or homopolymer is from about 5000 to about 30000.
- 18. A microcapsule of claim 14, wherein the polyester is hydroxybutyric acid/glycolic acid copolymer or homopolymer.
- 19. A microcapsule of claim 18, wherein the molar ratio of hydroxybutyric acid/glycolic acid of the copolymer or homopolymer is from about 100/0 to about 25/75.
- 20. A microcapsule of claim 18, wherein the weight average molecular weight of the hydroxybutyric acid/glycolic acid of the copolymer or homopolymer is from about 5000 to about 25000.
- 21. A method of treatment of diseases in the circulatory system, comprising the steps of:
- selecting a patient in need thereof; and
- administering to said patient a microcapsule of claim 1.
- 22. A method of treatment of thrombosis, angina pectoris, unstable angina or ischemic complication, reobstruction or restenosis after percutaneous transluminal coronary angioplasty or coronary thrombolytic therapy, comprising the steps of:
- selecting a patient in need thereof; and
- administering to said patient a microcapsule of claim 1.
- 23. A microcapsule which is produced by the steps of:
- selecting a dispersion of an amorphous water-soluble 2-piperazinone-1-acetic acid compound of the formula (I) or salt thereof as defined in claim 1;
- selecting a solution of a polymer in an organic solvent;
- dispersing in aqueous phase said dispersion of amorphous water-soluble 2-piperazinone-1-acetic acid or salt thereof and said polymer solution in organic solvent to obtain a solid/oil/water (s/o/w) emulsion; and
- subjecting the s/o/w emulsion to in-water drying.
- 24. A microcapsule of claim 23, wherein the concentration of the 2-piperazinone-1-acetic acid compound or salt thereof in the solution of a polymer in an organic solvent is from about 0.01 to about 75% (w/w).
- 25. A microcapsule of claim 23, wherein the solution of a polymer in an organic solvent further contains a basic compound, or oil or fat.
- 26. A microcapsule of claim 25, wherein the basic compound is a basic amino acid.
- 27. A microcapsule of claim 25, wherein the basic compound is L-arginine, L-lysine or N-methylglucamine.
- 28. A microcapsule of claim 25, wherein the concentration of the basic compound, or oil or fat in the solution of a polymer in an organic solvent is from about 0.1 to about 3% (w/w).
- 29. A microcapsule of claim 23, wherein the aqueous phase further contains an osmotic pressure adjustor.
- 30. A microcapsule of claim 29, wherein the osmotic pressure adjustor is a sodium chloride.
- 31. A method of producing a microcapsule, which comprises the steps of:
- selecting a dispersion of an amorphous water-soluble 2-piperazinone-1-acetic acid compound of the formula (I) or salt thereof as defined in claim 1;
- selecting a solution of a polymer in an organic solvent;
- dispersing in aqueous phase said dispersion of amorphous water-soluble 2-piperazinone-1-acetic acid or salt thereof and said polymer solution in organic solvent to obtain a solid/oil/water (s/o/w) emulsion; and
- subjecting the s/o/w emulsion to in-water drying.
- 32. A method according to claim 24, wherein said patient is a mammal.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8-077012 |
Mar 1996 |
JPX |
|
Parent Case Info
The application is a continuation-in-part of pending U.S. patent application Ser. No. 08/535,386, field Sep. 28, 1995.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4954298 |
Yamamoto et al. |
Sep 1990 |
|
5330767 |
Yamamoto et al. |
Jul 1994 |
|
5622657 |
Takada et al. |
Apr 1997 |
|
Foreign Referenced Citations (7)
Number |
Date |
Country |
0251476 |
Jan 1988 |
EPX |
0350246 |
Jul 1989 |
EPX |
0481732 |
Apr 1992 |
EPX |
529 858 |
Mar 1993 |
EPX |
11009 |
Apr 1995 |
EPX |
709 085 |
May 1996 |
EPX |
9113595 |
Sep 1991 |
WOX |
Non-Patent Literature Citations (1)
Entry |
J. Pharm. Sciences, vol. 75, No. 8 (1986) 750-755. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
535386 |
Sep 1995 |
|